Intec Pharma's total revenue is $0, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2021
Trailing 12 months ending Mar 2021
Intec Pharma posts a total revenue of $0 as of March 2021. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Intec Pharma's total revenue was $0. The latest reading is $0 (period ending March 2021). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a total revenue near $110B is typical. Intec Pharma's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Total Revenue is one piece of Intec Pharma's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for NTEC's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Intec Pharma's other metric pages and overview cover the third.